| 초록 |
Pharmaceutical industry has witnessed a growing number of biomolecular entities in competition with synthetic small molecules. Excellent target specificity and safety margin of biologics over small molecules are fueling such advancement. Recently, drug discovery efforts are in active transformation towards combining multiple preexisting biologics into a single molecular entity to achieve a higher efficacy and safety. In order to construct such a multifunctional biologics, chemical and biomolecular toolkits have been developed. The bioconjugation technology covalently interlocks two different molecules directly or through a chemical linker. The self-assembly technology utilizes a pair of peptidyl domains that non-covalently but specifically associate with each other to tag and tether multiple biomolecules into a hybrid agent. In this presentation, I will review recent technological advances, and applications thereof to design and construction of the multi-functional biologics. |
